Known targets — ChEMBL curated mechanism
ABL1ACEACHEACVR1ADRA1AADRA1BADRA1DADRA2AADRA2BADRA2CADRB1ADRB2ADRB3AGTR1ALKAVPR1AAVPR2BCHEBCRCA2CACNA1ACACNA1BCACNA1CCACNA1DCACNA1ECACNA1FCACNA1GCACNA1HCACNA1ICACNA1SCACNA2D1CACNA2D2CACNA2D3CACNA2D4CACNB1CACNB2CACNB3CACNB4CACNG1CACNG2CACNG3CACNG4CACNG5CACNG6CACNG7CACNG8CALCRLCASRCCR5CDK4CDK6CFBCHRM1CHRM2CHRM3CHRM4CHRM5CHRNA1CHRNA3CHRNA7CHRNB1CHRNB4CHRNDCHRNECHRNGCOXFA4COXFA4L2CRBNCSF1RCUL4ACYP19A1DDB1DPP4DRD1DRD2DRD3DRD4EDNRAEGFREML4ERBB2ERBB4ESR1ESR2FGFR1FGFR3FLT1FLT3FLT4GAAGABRA1GABRA2GABRA3GABRA4GABRA5GABRA6GABRB1GABRB2GABRB3GABRDGABREGABRG1GABRG2GABRG3GABRPGABRQGHSRGLAGNRHRGPD2GRIN1GRIN2AGRIN2BGRIN2CGRIN2DGRIN3AGRIN3BGSTP1HCN4HCRTR1HCRTR2HDAC1HDAC10HDAC11HDAC2HDAC3HDAC4HDAC5HDAC6HDAC7HDAC8HDAC9HRH1HRH2HRH3HSD11B1HSP90AA1HSP90AB1HTR1AHTR1BHTR1DHTR1EHTR1FHTR2AHTR2BHTR2CHTR3AHTR3BHTR3CHTR3DHTR3EHTR4HTR5AHTR6HTR7IMPDH1IMPDH2ITGA2BITGB3ITKJAK1JAK2KCNA1KCNA10KCNA2KCNA3KCNA4KCNA5KCNA6KCNA7KCNB1KCNB2KCNC1KCNC2KCNC3KCNC4KCND1KCND2KCND3KCNF1KCNG1KCNG2KCNG3KCNG4KCNH1KCNH2KCNH3KCNH4KCNH5KCNH6KCNH7KCNH8KCNJ2KCNJ3KCNJ5KCNK3KCNK9KCNQ1KCNQ2KCNQ3KCNQ4KCNQ5KCNS1KCNS2KCNS3KCNV1KCNV2KDRKITKLKB1LCKMMAOAMAOBMAPK14METMMP1MMP13MMP7MMP8MT-ND1MT-ND2MT-ND3MT-ND4MT-ND4LMT-ND5MT-ND6NDUFA1NDUFA10NDUFA11NDUFA12NDUFA13NDUFA2NDUFA3NDUFA5NDUFA6NDUFA7NDUFA8NDUFA9NDUFAB1NDUFAF1NDUFAF2NDUFAF3NDUFAF4NDUFB1NDUFB10NDUFB11NDUFB2NDUFB3NDUFB4NDUFB5NDUFB6NDUFB7NDUFB8NDUFB9NDUFC1NDUFC2NDUFS1NDUFS2NDUFS3NDUFS4NDUFS5NDUFS6NDUFS7NDUFS8NDUFV1NDUFV2NDUFV3NR3C1NS5ANTRK1NTRK2NTRK3ODC1OPRD1OPRK1OPRM1P2RY12PAHPARP1PDE3APDE3BPDE4APDE4BPDE4CPDE4DPDE5APDE7APDE7BPDE8APDE8BPDGFRAPDGFRBPIK3CAPIK3CDPNPPOLA1POLA2POLD1POLD2POLD3POLD4POLEPOLE2POLE3PPARGPRIM1PRIM2PRKCAPRKCBPRKCDPRKCEPRKCGPRKCHPRKCIPRKCQPRKCZPRKD1PRKD3PTGS1PTGS2RBX1RENRETROCK1ROCK2RPE65RRM1RRM2RRM2BS1PR1S1PR2S1PR3S1PR4S1PR5SCN10ASCN11ASCN1ASCN2ASCN3ASCN4ASCN5ASCN7ASCN8ASCN9ASCNN1ASCNN1BSCNN1GSIGMAR1SLC18A2SLC6A1SLC6A2SLC6A3SLC6A4SLC9A3SRCTACR1TOP1TOP2ATOP2BTTRTYMPdacAdacBdacCembAfolAftsIgyrAgyrBmrcAmrcBmrdAparCparEpolrplArplBrplCrplDrplErplFrplIrplJrplKrplLrplMrplNrplOrplPrplQrplRrplSrplTrplUrplVrplWrplXrplYrpmArpmBrpmCrpmDrpmErpmE2rpmFrpmGrpmG1rpmG2rpmG3rpmHrpmIrpmJrpsArpsBrpsCrpsDrpsErpsFrpsGrpsHrpsIrpsJrpsKrpsLrpsMrpsNrpsOrpsPrpsQrpsRrpsSrpsTrpsUykgMykgO
The experimentally established mechanism targets of Melphalan Flufenamide. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CHRM2 known ✓ | P08172 | 1/20 | 0.47 |
| ▸ | ADRA2A known ✓ | P08913 | 1/20 | 0.47 |
| ▸ | CHRM1 known ✓ | P11229 | 1/20 | 0.47 |
| ▸ | ACHE known ✓ | P22303 | 1/20 | 0.47 |
| ▸ | PTGS1 known ✓ | P23219 | 1/20 | 0.47 |
| ▸ | OPRM1 known ✓ | P35372 | 1/20 | 0.47 |
| ▸ | DRD3 known ✓ | P35462 | 1/20 | 0.47 |
| ▸ | SLC6A3 known ✓ | Q01959 | 1/20 | 0.47 |
| ▸ | KCNH2 known ✓ | Q12809 | 1/20 | 0.47 |
| ▸ | OPRK1 known ✓ | P41145 | 1/20 | 0.36 |
| ▸ | LMNA | P02545 | 2/20 | 0.48 |
| ▸ | CYP3A4 | P08684 | 3/20 | 0.47 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.47 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.47 |
| ▸ | ALOX15 | P16050 | 2/20 | 0.47 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.47 |
| ▸ | HIF1A | Q16665 | 2/20 | 0.47 |
| ▸ | MEN1 | O00255 | 2/20 | 0.47 |
| ▸ | ABCB11 | O95342 | 1/20 | 0.47 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Melphalan Flufenamide SCHEMBL29375249 | 0.89 | LMNA (0.52) | LMNACYP3A4KMT2AALDH1A1ALOX15 | |
| Melphalan Flufenamide SCHEMBL24101233 | 0.88 | LMNA (0.53) | LMNACYP3A4KMT2AALDH1A1ALOX15 | |
| Melphalan Flufenamide SCHEMBL18239898 | 0.88 | LMNA (0.53) | LMNACYP3A4KMT2AALDH1A1ALOX15 | |
| Melphalan Flufenamide SCHEMBL20208719 | 0.88 | LMNA (0.53) | LMNACYP3A4KMT2AALDH1A1ALOX15 | |
| SCHEMBL29635622 | 0.85 | CTSS (0.51) | LMNAKMT2ACTSSCTSK | |
| SCHEMBL29635623 | 0.85 | CTSS (0.51) | LMNAKMT2ACTSSCTSK | |
| SCHEMBL29635621 | 0.85 | CTSS (0.51) | LMNAKMT2ACTSSCTSK | |
| SCHEMBL24100695 | 0.83 | CYP3A4 (0.49) | LMNACYP3A4KMT2AALDH1A1ALOX15 | |
| SCHEMBL24101047 | 0.83 | LMNA (0.49) | LMNACYP3A4KMT2AALDH1A1ALOX15 | |
| SCHEMBL25021927 | 0.83 | CYP3A4 (0.48) | LMNACYP3A4KMT2AALDH1A1ALOX15 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250115637-A1 | COMPOUNDS CONTAINING DEUTERIUM | ONCOPEPTIDES INNOVATION AB (SE) | 2025-04-10 | — | — | US | claimed |
| EP-3866931-B1 | COMPOUNDS CONTAINING DEUTERIUM | ONCOPEPTIDES AB (SE) | 2023-02-15 | — | — | EP | claimed |
| US-12558337-B2 | Formulations comprising melflufen | ONCOPEPTIDES INNOVATION AB (SE) | 2026-02-24 | — | — | US | disclosed |
| US-20250205155-A1 | FORMULATIONS COMPRISING MELPHALAN FLUFENAMIDE AND CYCLODEXTRIN | ONCOPEPTIDES INNOVATION AB (SE) | 2025-06-26 | — | — | US | disclosed |
| US-20250115637-A1 | COMPOUNDS CONTAINING DEUTERIUM | ONCOPEPTIDES INNOVATION AB (SE) | 2025-04-10 | — | — | US | disclosed |
| CN-119053323-A | Formulation comprising melphalan fluorobenzamide and cyclodextrin | 肿瘤多肽创新股份公司 | 2024-11-29 | — | — | CN | disclosed |
| US-12152087-B2 | Deuterated melflufen compounds | ONCOPEPTIDES INNOVATION AB (SE) | 2024-11-26 | — | — | US | disclosed |
| US-20220184021-A1 | NOVEL FORMULATIONS COMPRISING MELFLUFEN | ONCOPEPTIDES AB (SE) | 2022-06-16 | — | — | US | disclosed |
| EP-3956032-A1 | NOVEL FORMULATIONS COMPRISING MELFLUFEN | Oncopeptides AB (SE) | 2022-02-23 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12558337-B2 | Formulations comprising melflufen | PHF8, EZH2, PHF2 | CHRM2 2676/4885ADRA2A 3247/4885CHRM1 3861/4885 |
| US-20250205155-A1 | FORMULATIONS COMPRISING MELPHALAN FLUFENAMIDE AND CYCLODEXTRIN | FUCA1, FGF2, FUCA2 | CHRM2 2716/4885ADRA2A 557/4885CHRM1 4096/4885 |
| US-20250115637-A1 | COMPOUNDS CONTAINING DEUTERIUM | DHX30, H1-10, REN | CHRM2 1614/4885ADRA2A 840/4885CHRM1 1200/4885 |
| US-12152087-B2 | Deuterated melflufen compounds | MC2R, MTNR1A, DHX30 | CHRM2 657/4885ADRA2A 641/4885CHRM1 732/4885 |
| US-20220184021-A1 | NOVEL FORMULATIONS COMPRISING MELFLUFEN | F12, FGF2, MC3R | CHRM2 900/4885ADRA2A 1638/4885CHRM1 2222/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.